Sign In
Buy MIRM
$91.84
-0.335 (-0.363%)
At Close: Jun 03, 2026
Mirum Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
08:45am, Wednesday, 03'rd Jan 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference.
Mirum (MIRM) Down on Failure of Mid-Stage Study on Livmarli
12:47pm, Tuesday, 19'th Dec 2023
Mirum (MIRM) faces a setback in its efforts to expand its lead drug Livmarli's label for the indication of biliary atresia in patients who have undergone a Kasai surgery.
Mirum Pharmaceuticals: Market Overreacts To Livmarli's Phase 2 Miss
09:10am, Tuesday, 19'th Dec 2023
Mirum Pharmaceuticals, Inc. stock dropped 16% after its lead asset, Livmarli, failed to meet primary or secondary endpoints in a phase 2 trial for biliary atresia. This looks like an overreaction cons
Mirum Pharmaceuticals to Present at the 2023 Evercore ISI HealthCONx Conference
04:05pm, Monday, 20'th Nov 2023
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the 2023 Evercore ISI HealthCONx Conference.
Mirum Pharmaceuticals, Inc. (MIRM) Q3 2023 Earnings Call Transcript
01:51am, Sunday, 05'th Nov 2023
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Andrew McKibben - VP, IR and Finance Christopher Peetz - President, CEO & D
Mirum Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023
08:45am, Friday, 27'th Oct 2023
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023.
7 Small-Cap Stocks That Get the Nod from Wall Street
04:52pm, Wednesday, 11'th Oct 2023
While enterprises with diminutive market capitalizations tend to be high-risk, high-reward ventures, you can shift the odds in your favor with small-cap stocks with buy ratings. Thanks to the nod from
Mirum Pharmaceuticals: An Attractive Stock To Watch For Its Liver Disease Franchise
03:51am, Sunday, 24'th Sep 2023
Mirum Pharmaceuticals has two drugs, maralixibat and volixibat, targeting rare liver diseases involving cholestasis. The company's lead program, maralixibat, was approved for Alagille syndrome and has
Strength Seen in Mirum Pharmaceuticals, Inc. (MIRM): Can Its 8.0% Jump Turn into More Strength?
07:31am, Friday, 15'th Sep 2023
Mirum Pharmaceuticals, Inc. (MIRM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher i
Mirum Pharma (MIRM) Stock Rises 42% Year to Date: Here's Why
12:47pm, Wednesday, 06'th Sep 2023
Mirum Pharma (MIRM) surges 42% year to date due to encouraging progress in label-expansion efforts of Livmarli, along with strategic initiatives, to expand its commercial portfolio.
Mirum Pharmaceuticals, Inc. (MIRM) Q2 2023 Earnings Call Transcript
11:42am, Saturday, 05'th Aug 2023
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Andrew McKibben – Vice President-Investor Relations and Finance Chris Peetz
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates
06:46pm, Thursday, 03'rd Aug 2023
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to loss of $0.84 per share a year ago.
Mirum: Must Watch Biotech On Release Of Results From EMBARK Study
11:01am, Sunday, 09'th Jul 2023
Results from the phase 2b EMBARK study, which is using LIMVARLI for the treatment of patients with biliary atresia, are expected in the 2nd half of 2023. It is expected that the global Biliary Atresia
Mirum Pharmaceuticals to Present New LIVMARLI Data at the 2023 EASL Congress
08:30am, Wednesday, 07'th Jun 2023
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--Mirum Pharmaceuticals to Present New LIVMARLI Data at the 2023 EASL Congress.
Mirum Pharmaceuticals, Inc. (MIRM) Q1 2023 Earnings Call Transcript
07:42am, Sunday, 07'th May 2023
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q1 2023 Earnings Conference Call May 6, 2023 4:30 PM ET Company Participants Andrew McKibben - Vice President, Investor Relations and Finance Chris Peetz - P
